摘要
目的观察国产Nano无载体药物支架对血清炎症因子的影响,并探讨其对减少主要不良心脏事件的作用。方法选择2012年1月至2013年10月我院拟行经皮冠状动脉介入治疗(PCI)术的冠心病患者59例随机分为Partner组和Nano组,分别用ELISA法检测术前、术后24 h、1个月、3个月、6个月及12个月血清炎症因子高敏C反应蛋白(hs CRP)、白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9);术后1、3、6、10、12个月门诊或电话随访,观察有无主要不良心脏事件。结果 25例患者成功置入Partner药物支架,34例置入Nano无载体药物支架。Partner组和Nano组术前基本情况无明显差异,术后24 h hs CRP、IL-6、MMP-9均达到最高值;术前、术后24 h、术后1、3个月两组间hs CRP、IL-6、MMP-9无明显差异(P>0.05);术后6个月Partner组IL-6、MMP-9明显高于Nano组(P<0.05),但两组间hs CRP无明显差异(P>0.05);术后12个月Partner组炎症因子hs CRP、IL-6、MMP-9均明显高于Nano组(P均<0.05)。随访期间Partner组发生主要不良心脏事件明显高于Nano组(P<0.05)。结论 Nano组较Partner组炎症反应更低,进一步减少支架置入术后主要不良心脏事件,考虑与去除载体有关。
ObjectiveTo study the effect of polymer-free sirolimus-eluting Nano stent implantation on plasma proinflammatory cytokines.MethodsFrom January 2012 to October 2013, 59 patients with coronary heart disease treated with primary percutaneous coronary intervention （PCI） were enroled and randomly divided into Partner and Nano group. Plasma proinflammatory cytokines high-sensitivity C-reactive protein （hsCRP）, interleukin 6 （IL-6） and matrix metaloproteinases 9 （MMP-9） were detected by ELISA in the preoperative and postoperative 24 hours, 1 month, 3 months, 6 months and 12 months. All patients were folowed up in postoperative 1, 3, 6, 10, 12 months. The major adverse cardiac events （MACE） were analyzed.Results25 patients were implanted Partner stents and 34 patients were implanted Nano stents. Immediate success rate of postoperation was 100%. There was no difference on the preoperative basic situation between Partner and Nano group. The concentration of hsCRP, IL-6, MMP-9 achieved the highest in postoperative 24 hours. There was no difference on the concentration of hsCRP, IL-6, MMP-9 in preoperative and postoperative 24 hours, 1 month, 3 months between Partner and Nano group. Plasma IL-6, MMP-9 of Partner group were significantly higher than that of Nano group （P〈0.05）, but there was no difference in plasma hsCRP （P〉0.05） in postoperative 6 months between two groups. Plasma hsCRP, IL-6 and MMP-9 of Partner group were significantly higher than that of Nano group in postoperative 12 months （alP〈0.05）. There were more MACE in Partner group than Nano group during the 12 months folow-up （P〈0.05）.ConclusionsNano group had lower inflammatory response and less MACE after stent implantation, that was related to get rid of the carrier.
出处
《中华临床医师杂志（电子版）》
CAS
2015年第15期40-43,共4页
Chinese Journal of Clinicians(Electronic Edition)
关键词
Nano无载体药物支架
Partner药物支架
炎症因子
主要不良心脏事件
Polymer-free sirolimus-eluting Nano stent
Sirolimus-eluting Partner stent
Plasma proinflammatory cytokines
Major adverse cardiac events
